Ordering
Available Variants5 mg
CHA.70027-5mg
Price
€74.32
Available – Dispatch in 14 days
25 mg
CHA.70027-25mg
Price
€300.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.70027-5mg | €74.32 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.70027-25mg | €300.00 |
≥98% (HPLC), powder, VRAC or VSOAC blocker
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C22H28Cl2O4 |
|---|---|
| CAS Number | 82749-70-0 |
| Molecular Weight | 427.36 |
| NACRES | NA.77 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD07783995 |
| Assay | ≥98% (HPLC) |
| Form | powder |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
DCPIB, also known as 4-(2-Butyl-6,7-dichloro-2-cyclopentylindan-1-on-5-yl) oxobutyric acid, is a synthetic compound with a CAS number of 82749-70-0. It is a potent and selective antagonist of the transient receptor potential vanilloid 4 (TRPV4) channel, which plays a crucial role in various physiological processes, including mechanoreception, osmoregulation, and inflammation. DCPIB has been widely used as a research tool to study the function and regulation of TRPV4 channels in different cell types and tissues. Its high affinity and specificity for TRPV4 channels make it a valuable compound for investigating the pathophysiological roles of these channels in diseases such as cardiovascular disorders, cancer, and neurodegenerative diseases. Further research is needed to fully elucidate the therapeutic potential of DCPIB and its potential applications in clinical settings.
